Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors

Skowron, 2015, Genetic and molecular alterations across medulloblastoma subgroups, J. Mol. Med. (Berl.), 93, 1075, 10.1007/s00109-015-1333-8

Pui, 2011, Challenging issues in pediatric oncology, Nat. Rev. Clin. Oncol., 8, 540, 10.1038/nrclinonc.2011.95

DeSouza, 2014, Pediatric medulloblastoma - update on molecular classification driving targeted therapies, Front. Oncol., 4, 176, 10.3389/fonc.2014.00176

Gajjar, 2014, Medulloblastoma-translating discoveries from the bench to the bedside, Nat. Rev. Clin. Oncol., 11, 714, 10.1038/nrclinonc.2014.181

Versteege, 1998, Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer, Nature, 394, 203, 10.1038/28212

Morgenstern, 2010, Clinical and pathological features of paediatric malignant rhabdoid tumours, Pediatr. Blood Cancer, 54, 29, 10.1002/pbc.22231

Pol, 2014, Trial watch: oncolytic viruses for cancer therapy, OncoImmunology, 3, e28694, 10.4161/onci.28694

Dolgin, 2015, Oncolytic viruses get a boost with first FDA-approval recommendation, Nat. Rev. Drug Discov., 14, 369, 10.1038/nrd4643

Kaufmann, 2013, Oncolytic virotherapy for gliomas: steps toward the future, CNS Oncol., 2, 389, 10.2217/cns.13.35

Donnelly, 2012, Recent clinical experience with oncolytic viruses, Curr. Pharm. Biotechnol., 13, 1834, 10.2174/138920112800958904

Studebaker, 2012, Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma, Neuro-oncol., 14, 459, 10.1093/neuonc/nor231

Studebaker, 2015, Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors, Neuro-oncol., 17, 1568, 10.1093/neuonc/nov058

Lasner, 1996, Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS, J. Neuropathol. Exp. Neurol., 55, 1259, 10.1097/00005072-199612000-00010

Friedman, 2016, Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses, Neuro-oncol., 18, 227, 10.1093/neuonc/nov123

Chase, 1998, An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy, Nat Biotechnol., 16, 444, 10.1038/nbt0598-444

Clarke, 1989, Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation, Cancer Res., 49, 2344

Currier, 2008, Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide, Mol. Ther., 16, 879, 10.1038/mt.2008.49

Goldstein, 1988, Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant, Virology, 166, 41, 10.1016/0042-6822(88)90144-4

Goldstein, 1988, Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant, J. Virol., 62, 196, 10.1128/JVI.62.1.196-205.1988

Hu, 2006, A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor, Clin. Cancer Res., 12, 6737, 10.1158/1078-0432.CCR-06-0759

Kaufman, 2010, Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma, Ann. Surg. Oncol., 17, 718, 10.1245/s10434-009-0809-6

Nomura, 2009, Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases, Cancer Chemother. Pharmacol., 63, 321, 10.1007/s00280-008-0742-6

Kaur, 2012, Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress, Curr. Pharm. Biotechnol., 13, 1842, 10.2174/138920112800958814

Chou, 1995, Proc. Natl. Acad. Sci. USA, 92, 10516, 10.1073/pnas.92.23.10516

Kanai, 2012, Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors, J. Virol., 86, 4420, 10.1128/JVI.00017-12

Pawlik, 2002, Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene, Cancer, 95, 1171, 10.1002/cncr.10776

Pawlik, 2000, Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus, Cancer Res., 60, 2790

Freeman, 1993, The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 53, 5274

Bi, 1993, In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy, Hum. Gene Ther., 4, 725, 10.1089/hum.1993.4.6-725

Hagler, 1968, Cerebellar medulloblastoma chemotherapeutic remission with vincristine cyclophosphamide and methotrexate, Cancer, 21, 912, 10.1002/1097-0142(196805)21:5<912::AID-CNCR2820210514>3.0.CO;2-D

Friedman, 1986, Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma, Neurosurgery, 18, 335, 10.1227/00006123-198603000-00014

Friedman, 1995, Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again), J. Neurooncol., 24, 103, 10.1007/BF01052667

Kim, 2013, Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients, Childs Nerv. Syst., 29, 1851, 10.1007/s00381-013-2163-z

Gotti, 2015, A case of relapsing spinal atypical teratoid/rhabdoid tumor (AT/RT) responding to vinorelbine, cyclophosphamide, and celecoxib, Childs Nerv. Syst., 31, 1621, 10.1007/s00381-015-2755-x

D’cunja, 2007, Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells, Eur. J. Cancer, 43, 1581, 10.1016/j.ejca.2007.03.003

Studebaker, 2010, Treatment of medulloblastoma with a modified measles virus, Neuro-oncol., 12, 1034, 10.1093/neuonc/noq057

Krisky, 1998, Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons, Gene Ther., 5, 1593, 10.1038/sj.gt.3300766

Goins, 2014, Engineering HSV-1 vectors for gene therapy, Methods Mol. Biol., 1144, 63, 10.1007/978-1-4939-0428-0_5